Yahoo · Sep 18, 2026
All 50 States Joining Medicaid Drug Pricing Model After Pharma Deals, Trump Says
Drug companies had incentives to participate in the deals to stave off the threat of U.S. tariffs on their products.
NYSE · PFE
Pfizer Inc.
Healthcare · Drug Manufacturers - General
$27.66
Down-$0.04 (-0.14%)
Updated Sep 20, 2026, 8:37 AM
SID Score
7.0/10
Composite research score
Smart Money
71/100
Bullish
- Market cap
- 146.75B
- P/E ratio
- 14.94
- Dividend yield
- 6.22%
- 52-week range
- $23.62 – $29.21
- Volume
- 75.59M
- Avg. volume
- 68.83M
Price performance
PFE price history
1M range · 19 trading sessions · Daily adjusted prices
PFE closed at $27.66 after 19 trading sessions, down 1.11% for the selected period.
- Last close
- $27.66
- Period change
- -1.11%
- Period low
- $27.46
- Period high
- $29.02
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $27.64 | $27.66 | $27.34 | $27.66 | 75.59M |
| Sep 17, 2026 | $27.62 | $27.81 | $27.55 | $27.64 | 29.01M |
| Sep 16, 2026 | $27.64 | $27.69 | $27.36 | $27.46 | 26.05M |
| Sep 15, 2026 | $27.615 | $27.66 | $27.245 | $27.55 | 40.44M |
| Sep 14, 2026 | $28.08 | $28.19 | $27.685 | $27.72 | 28.57M |
| Sep 11, 2026 | $27.80 | $27.85 | $27.42 | $27.72 | 25.56M |
| Sep 10, 2026 | $27.69 | $27.75 | $27.40 | $27.65 | 28.81M |
| Sep 9, 2026 | $27.76 | $27.975 | $27.57 | $27.78 | 29.14M |
| Sep 8, 2026 | $28.015 | $28.145 | $27.715 | $27.79 | 31.77M |
| Sep 4, 2026 | $28.58 | $28.69 | $28.38 | $28.45 | 23.79M |
| Sep 3, 2026 | $29.09 | $29.21 | $28.44 | $28.81 | 26.72M |
| Sep 2, 2026 | $28.79 | $29.09 | $28.705 | $29.02 | 39.28M |
| Sep 1, 2026 | $28.818 | $29.09 | $28.465 | $28.55 | 42.49M |
| Aug 31, 2026 | $27.85 | $28.70 | $27.64 | $28.46 | 45.93M |
| Aug 28, 2026 | $28.00 | $28.02 | $27.77 | $27.96 | 27.18M |
| Aug 27, 2026 | $27.97 | $28.18 | $27.83 | $28.02 | 31.17M |
| Aug 26, 2026 | $28.44 | $28.50 | $28.145 | $28.30 | 35.07M |
| Aug 25, 2026 | $27.915 | $28.58 | $27.84 | $28.57 | 31.92M |
| Aug 24, 2026 | $28.10 | $28.1561 | $27.81 | $27.97 | 23.85M |
Latest PFE news
The latest Smart Investors Daily articles mentioning PFE.
Stock researchCompany · Overview
PFE research
Overview
Company profile and research snapshot.
Company profile
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $30.00
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Hold | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
| Jul 13, 2026 | Guggenheim | Buy | — |
| Jul 13, 2026 | BMO Capital | Outperform | — |
| Jul 10, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 18, 2026
Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and th
Yahoo · Sep 18, 2026
Trump to Announce Medicaid Drug Pricing After Pharma Deals
Drug companies had incentives to participate in the deals to stave off the threat of U.S. tariffs on their products.
Yahoo · Sep 18, 2026
Pfizer (PFE), What Is Drawing Fresh Attention Now?
Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching how management frames dividend priorities, recent pipeline setbacks, and the evolving role of newer oncology partnerships. At a share price of US$27.64, Pfizer has logged a 9.8% year to date share price return and a 22.5% total shareholder return over the past 12 months. This represents a rebound that has built momentum over the last three months as dividend messaging,...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
